SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are facing downward pressure as investors react to the company's aggressive $40 billion financing plan to fund massive capital expenditures for AI infrastructure, despite the company posting strong earnings and a record-breaking $638 billion revenue backlog. The community remains deeply divided, with some investors aggressively buying the dip on the belief that the backlog and AI expansion create a long-term winner, while skeptics warn that the heavy debt and equity dilution are unsustainable burdens.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is seeing intense volatility as investors react to a large-scale capital raise and concurrent equity offerings designed to fund a massive $39 billion backlog of AI server orders. While some community members are treating the resulting sell-off as a strategic buying opportunity driven by genuine demand, others remain deeply skeptical, expressing concerns over share dilution, management credibility, and the potential impact of ongoing regulatory scrutiny.

SpaceX

The upcoming SpaceX IPO is driving significant market volatility as investors rotate out of technology and semiconductor stocks to free up liquidity for the massive $75 billion offering. While the deal is heavily oversubscribed, community sentiment is sharply divided between believers in long-term space and AI infrastructure potential and skeptics warning of a classic exit-liquidity trap for retail participants.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Market sentiment remains highly volatile as investors weigh ongoing geopolitical tensions in the Middle East against upcoming inflation data and central bank policy decisions. The community is actively debating the durability of recent relief rallies, with many questioning whether these moves are sustainable or merely short-term liquidity traps driven by algorithmic trading and election-year posturing.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as investors react to strong earnings and raised revenue guidance, fueling optimism about its core product growth and pipeline potential. Community sentiment remains bullish, with many focusing on the long-term blockbuster potential of its specialty pharmaceutical portfolio and the upcoming Phase 3 advancement of its pipeline assets.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust is experiencing heightened volatility as investors weigh escalating geopolitical tensions in the Middle East against persistent inflationary pressures following hot PPI data. The community remains divided, with active debates centered on whether current market pullbacks present a tactical buying opportunity or signal a deeper structural correction amidst broader sector rotation.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

The Defiance Daily Target 2X Long SMCI ETF ($SMCX) is experiencing intense volatility and trading volume, driven by ongoing market concerns surrounding its underlying asset, SMCI, and high investor anxiety regarding potential delisting, reverse splits, and severe performance decay. Community discourse is deeply polarized, featuring active scalpers attempting to profit from sharp daily swings while many long-term holders express frustration over significant losses and the risks inherent in holding leveraged instruments amid negative news cycles.

Purecycle Technologies, Inc. engages in recycling waste polypropylene into virgin polymer. Its process includes two steps: Feed Pre-Processing and the use of the Technology for purification. The company was founded by John Scott in September 2015 and is headquartered in Orlando, FL.

PureCycle Technologies Inc

PureCycle Technologies is seeing heightened investor attention and bullish sentiment following a significant $395 million capital raise to restructure debt and fund long-term growth, coupled with positive technical momentum that has the community discussing potential squeeze scenarios. Traders are closely monitoring the company's progress in securing commercial orders and navigating regulatory certifications to validate its long-term viability in the recycling sector.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is gaining significant momentum as investors digest strong performance data from its prediction market platform and anticipate a surge in betting volume surrounding the upcoming World Cup and professional sports finals. The stock is currently the focus of intense community debate, with bulls citing a potential breakout and long-term tailwinds from expanded product offerings, while skeptics remain critical of management's history of underperformance and persistent volatility.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera shares have experienced significant volatility following a quarterly report that revealed lower-than-anticipated revenue and a moderated timeline for commercial milestones. While the community is actively debating the company's long-term potential in next-generation chip architectures, recent price action is being driven by institutional rebalancing and a cooling of speculation regarding immediate licensing deals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock

What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, June 3, 2026 SAN FRANCISCO, June 3, 2026 /PRNewswire/ --Nektar Therapeutics (NASDAQ: NKTR) today announced...

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York PR Newswire SAN FRANCISCO, May 27, 2026 SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar...

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch

Key PointsProsight Management increased its Nektar Therapeutics holding by 180,367 shares last quarter, an estimated $10.27 million buy based on average prices during the quarter...

Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus

NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.

Nektar Therapeutics Reports First Quarter 2026 Financial Results

Nektar Therapeutics Reports First Quarter 2026 Financial Results Nektar Therapeutics Reports First Quarter 2026 Financial Results PR Newswire SAN FRANCISCO, May 7, 2026 SAN FRANCISCO, May 7, 2026...

NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May...

NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit

NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit PR Newswire NEW YORK, May 4, 2026 NEW YORK, May 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a...

Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming May 5, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors...

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

NKTRNektar Therapeutics

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NKTR News